Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Lancet Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(11)70296-0PMID 22177579
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effi cacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia : a randomised controlled trial

  2010cited by this paper
• Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme

  2010cited by this paper
• Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

  2010cited by this paper
• HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study

  2010cited by this paper
• HPV screening for cervical cancer in rural India.

  2009cited by this paper
• Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

  2009cited by this paper
• HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

  2009cited by this paper
• HPV screening for cervical cancer in rural India.

  2009cited by this paper
• Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

  2009cited by this paper
• Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

  2008cited by this paper
• Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer

  2008cited by this paper
• Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

  2007cited by this paper
• Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

  2007cited by this paper
• Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

  2006cited by this paper
• Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

  2006cited by this paper
• Overview of the European and North American studies on HPV testing in primary cervical cancer screening

  2006cited by this paper
• The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996

  2004cited by this paper
• POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women

  2004cited by this paper
• Epidemiologic classification of human papillomavirus types associated with cervical cancer.

  2003cited by this paper
• Premalignant and malignant squamous lesions of the cervix

  2003cited by this paper
• GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes

  2002cited by this paper
• The 2001 Bethesda System: terminology for reporting results of cervical cytology.

  2002cited by this paper
• Cervical cancer screening in the Netherlands.

  2000cited by this paper
• High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy

  2000cited by this paper
• Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study.

  1999cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper
• A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings

  1997cited by this paper
• PCR‐based high‐risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears

  1996cited by this paper
• Human papillomavirus in false negative archival cervical smears: implications for screening for cervical cancer.

  1995cited by this paper
• The presence of persistent high‐risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months

  1995cited by this paper
• Obstetrical and Gynaecological Pathology

  1995cited by this paper
• BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT

  1995cited by this paper
• Human papillomavirus and invasive cervical cancer in Brazil.

  1994cited by this paper
• Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening.

  1992cited by this paper
• Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia

  1991cited by this paper
• Precancerous lesions in the cervix

  1980cited by this paper

• Head-to-head comparison of the MyGene human papillomavirus-sexually transmitted infection assay versus the Cobas 4800 human papillomavirus test for detecting high-grade cervical intraepithelial neoplasia.

  2026cites this paper
• A paper-based HPV E7 oncoprotein assay for cervical precancer detection at the point of care

  2025cites this paper
• Evaluating the trend of time to colposcopy follow-up among women with a positive primary human papillomavirus screening result at Kaiser Permanente Southern California.

  2025cites this paper
• Diagnostic Utility of Human Papilloma Virus Testing in Comparison with Pap Cytology and Histopathology in Unvaccinated Women with Cervical High-Grade Dysplasia and Carcinoma in Botswana

  2025cites this paper
• Improving Efficiency in Dutch Cervical Screening by Genotyping: An Analysis of Real World Program Data

  2025cites this paper
• A pragmatic randomized trial to compare strategies for implementing primary HPV testing for routine cervical cancer screening in a large healthcare system

  2025cites this paper
• The Distribution of Oncogenic HPV Types Between CIN 2 and 3: A Retrospective Study

  2025cites this paper
• Comparison of Clinical Efficacy of Liquid-Based Cytology and High-Risk Human Papillomavirus Testing With Partial Genotyping in Cervical Screening of Women Below 30 Years Old

  2025cites this paper
• A Pilot Study on the Feasibility and Integration of High-Risk Human Papillomavirus (HPV) Testing for Cervical Cancer Prevention in Trinidad and Tobago

  2025cites this paper
• Impact of Single- Versus Multiple-Type HPV Infections on Cervical Cytological and Histological Abnormalities: The Dominant Oncogenic Potential of HPV16 Single-Type Infections

  2025cites this paper
• Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

  2025cites this paper
• A prevalence-incidence-clearance model for interval-censored screening and surveillance data in a population with an elevated disease risk at baseline

  2025cites this paper
• Under which realistic circumstances is hrHPV self‐sampling increasing cervical screening effectiveness in a partly vaccinated population? A modelling study

  2025influential citation
• Addressing the burden of cervical cancer for Indigenous women in Latin America and the Caribbean: a call for action

  2024cites this paper
• Metaproteomic analysis from cervical biopsies and cytologies identifies proteinaceous biomarkers representing both human and microbial species.

  2024cites this paper
• Primary Human Papillomavirus Screening: Women’s Perceptions of New Cervical Cancer Screening Recommendations

  2024cites this paper
• Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study

  2024cites this paper
• Principles of cancer screening

  2024cites this paper
• Comparison of cervical cancer screening models based on Pap and HPV tests in Tbilisi, Georgia.

  2024cites this paper
• Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low‐grade cytology from a population‐based Dutch primary HPV screening trial

  2024cites this paper
• Something old, something new: Cervical cytopathology in the new era

  2024cites this paper
• Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China

  2024cites this paper
• Colposcopy referral and CIN3+ risk of human papillomavirus genotyping strategies in cervical cancer screening.

  2024cites this paper
• Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.

  2024cites this paper
• Acceptability of self-collected vaginal samples for human papillomavirus testing for primary cervical cancer screening: comparison of face-to-face and online recruitment modes

  2024cites this paper
• Evaluation of C-C Motif Chemokine Receptor 5 (CCR5) as a Sample Adequacy Control in HPV Molecular Diagnostics

  2024cites this paper
• Accuracy and Reproducibility of Cytology Triage in a HPV-Based Primary Screening Setting: A Revision of 384 Pap Tests

  2023cites this paper
• Virus del papiloma humano y cáncer de orofaringe

  2023cites this paper
• HPV Testing and its Role in Cervical Cancer Screening

  2023cites this paper
• Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study

  2023cites this paper
• Clinical efficacy of primary human papillomavirus (HPV) screening with partial genotyping for HPV-16 and HPV-18 subtypes in women from 25 years old.

  2023cites this paper
• Diagnostic outcomes after colposcopy at a tertiary clinic for women aged 50–74 referred after detection of oncogenic human papillomavirus at primary screening

  2023cites this paper
• Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.

  2023cites this paper
• HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK

  2023cites this paper
• Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations

  2023cites this paper
• Identification of a methylation panel as an alternative triage to detect CIN3+ in hrHPV-positive self-samples from the population-based cervical cancer screening programme

  2023cites this paper
• Analysis of the cervical microbiome in women from the German national cervical cancer screening program

  2023cites this paper
• Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India

  2023cites this paper
• Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study

  2023cites this paper
• Does the New National Cervical Screening Programme Guideline Detect Cases of High-Grade Squamous Intraepithelial Lesions That Previously Would Have Been Missed?

  2023cites this paper
• Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening?

  2023cites this paper
• Home‐based self‐sampling vs clinician sampling for anal precancer screening: The Prevent Anal Cancer Self‐Swab Study

  2023cites this paper
• Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.

  2023cites this paper
• Detection of cervical high-grade squamous intraepithelial lesions and assessing diagnostic performance of colposcopy among women with oncogenic HPV

  2023cites this paper
• Cervical Cancer Screening and Prevention

  2023cites this paper
• Evaluation of the applicability of internal controls on self-collected samples for high-risk human papillomavirus is needed

  2023cites this paper
• Prevalence of human papillomavirus infection in abnormal pap smears

  2023cites this paper
• Current approaches and challenges to cervical cancer prevention in the United States

  2023cites this paper
• Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany

  2023cites this paper
• Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.

  2023cites this paper
• HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial

  2023cites this paper
• Prevalence of Human Papillomavirus (HPV) Genotypes among Women During 2015–2020 in Mashhad, Iran

  2023cites this paper
• Role of Dual-Staining p16/Ki-67 in the Management of Patients under 30 Years with ASC-US/L-SIL

  2022cites this paper
• Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection

  2022cites this paper
• National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study

  2022cites this paper
• Shift in harms and benefits of cervical cancer screening in the era of HPV screening and vaccination: a modelling study

  2022cites this paper
• Papillomavirus humain et cancer de l’oropharynx

  2022cites this paper
• Absolute Risk and Attributable Fraction of Type-Specific Human Papillomavirus in Cervical Cancer and Precancerous Lesions—A Population-Based Study of 6286 Women in Rural Areas of China

  2022cites this paper
• Risk of cervical precancer among HPV–negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study

  2022cites this paper
• Implementing HPV testing in 9 Latin American countries: The laboratory perspective as observed in the ESTAMPA study

  2022cites this paper
• Incorporating HPV 33 and cytology into HPV 16/18 screening may be feasible. A cross-sectional study

  2022cites this paper
• Cytology, High-Risk Human Papillomavirus Testing and Serum CA19-9 in a Large Cohort of Patients with Invasive Cervical Adenocarcinomas: Correlation with a New Pathogenetic Classification

  2022cites this paper
• Alternative cytology triage strategies for primary HPV screening.

  2022cites this paper
• Proposal for a descriptive and differentiated presentation of the longitudinal impact of the new organized cancer screening guideline and HPV vaccination in Germany

  2022cites this paper
• Randomized Implementation of a Primary Human Papillomavirus Testing–based Cervical Cancer Screening Protocol for Women 34 to 69 Years in Norway

  2022cites this paper
• Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment

  2022cites this paper
• Implementation of a centralized HPV-based cervical cancer screening programme in Tuscany: First round results and comparison with the foregoing Pap-based screening programme

  2022cites this paper
• Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer ≥15 years later

  2022cites this paper
• Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high‐risk human papillomavirus‐positive population

  2022cites this paper
• Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population

  2022cites this paper
• Detection and Outcome of Endocervical Atypia in Cytology in Primary HPV Screening Programme

  2021cites this paper
• Implementing community-based human papillomavirus self-sampling with SMS text follow-up for cervical cancer screening in rural, southwestern Uganda

  2021cites this paper
• Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4/miR124-2 methylation and HPV genotyping

  2021cites this paper
• Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: An observational study

  2021cites this paper
• The IARC Perspective on Cervical Cancer Screening.

  2021cites this paper
• Rising Burden of Gynaecological Cancers in Developing Countries

  2021cites this paper
• CMAR_A_328279 6869..6877

  2021cites this paper
• HPV-Diagnostik und Therapie in der Prävention

  2021cites this paper
• Cost-Effectiveness and Budget Impact Analysis of Primary Screening With Human Papillomavirus Test With Genotyping in Argentina.

  2021cites this paper
• The impact of primary human papillomavirus screening on negative loop excision histology following biopsy‐proven high‐grade cervical intra‐epithelial lesions: A review from a large tertiary colposcopy unit

  2021cites this paper
• A Bayesian accelerated failure time model for interval censored three-state screening outcomes

  2021cites this paper
• Novel Antigenic Targets of HPV Therapeutic Vaccines

  2021cites this paper
• Clinical evaluation of a real-time optoelectronic device in cervical cancer screening.

  2021cites this paper
• Comparison of biopsy results of HPV 16/18 and non-16/18 HPV positive patients with a normal PAP test, a tertiary center experience

  2021cites this paper
• Rationale and design of the Prevent Anal Cancer Self-Swab Study: a protocol for a randomised clinical trial of home-based self-collection of cells for anal cancer screening

  2021cites this paper
• Primary HPV cervical screening: Clinical audit of outcomes of women seen at a tertiary referral centre for colposcopy in Australia

  2021cites this paper
• Impact of educational intervention on cervical cancer screening uptake among reproductive age women

  2021cites this paper
• Updated evidence-based recommendations for cervical cancer screening in France

  2021cites this paper
• Classification of high‐grade cervical intraepithelial neoplasia by p16ink4a, Ki‐67, HPV E4 and FAM19A4/miR124‐2 methylation status demonstrates considerable heterogeneity with potential consequences for management

  2021cites this paper
• The first-round results of a population-based cohort study of HPV testing in Japanese cervical cancer screening: baseline characteristics, screening results, and referral rate

  2021cites this paper
• Hybrid capture 2 and cobas® 4800: Comparison of performance of two clinically validated tests for human papillomavirus primary screening of cervical cancer

  2021cites this paper
• The meaning of high‐risk HPV other than type 16/18 in women with negative cytology: Is it really safe to wait for 1 year?

  2021influential citation
• Comparison of Aptima and hybrid capture‐2 HPV tests and Pap test in the referral population in Japan

  2021cites this paper
• Targeting autophagy in disease: established and new strategies

  2021cites this paper
• Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.

  2021cites this paper
• HPV Genotype Specific and Age Stratified Immediate Prevalence of Cervical Precancers and Cancers in Women with NILM/hrHPV+: A Single Center Retrospective Study of 26,228 Cases

  2021cites this paper
• Servikal kanser taramasında saptanan önemi belirlenemeyen atipik skuamoz hücrelerin klinik öneminin değerlendirmesi: Eskişehir deneyimi Evaluation of the clinical significance of atypical squamous cells, whose significance could not be determined in cervical cancer screening: Eskişehir experience

  2021cites this paper
• Options for triage and implications for colposcopists within European HPV-based cervical screening programmes.

  2021cites this paper
• Servikal kanser taramasında saptanan önemi belirlenemeyen atipik skuamoz hücrelerin klinik değerlendirmesi: Eskişehir deneyimi

  2021cites this paper
• Comparison Study of Self-Sampled and Physician-Sampled Specimens for High-Risk Human Papillomavirus Test and Cytology

  2020cites this paper